Research Area Hepatitis

A5394 - Seguridad, tolerabilidad e impacto del selgantolimod, agonista oral de TLR8, sobre el HBsAg (antígeno de superficie del virus de la Hepatitis B) en participantes con hepatitis B crónica y VIH

Open and enrolling

See locations

A5394: Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV

Open and enrolling

See locations

A5128: Plan for Obtaining Informed Consent to use Stored Human Biological Materials (HBM) for Currently Unspecified Analysis.

Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses. Informed…

Open and enrolling

See locations

A5243: Non-US Genomic Sampling

Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing. This is a…

Closed to accrual

See locations

A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)

This is a study to treat participants, with or without HIV, who are found to have been recently infected with…

Closed to accrual

Up to 28 weeks on Step 1 and up to an additional 40 weeks if on Step 2.

See locations

A5379: B-ENHANCEMENT OF HBV VACCINATION IN PERSONS LIVING WITH HIV (BEe-HIVe): Evaluation of HEPLISAV-B

A5379 is a study looking at hepatitis B vaccination in adults living with HIV. Hepatitis B is a serious viral…

Closed to accrual

72 weeks

See locations